摘要
目的：探讨非骨髓清除性预处理方案（nonmyeloablative conditioning regimen， NACR）加异基因造血干细胞移植（allo－HSCT）治疗血液系恶性肿瘤的可行性及其效果。方法：本报告用Fludarabine 180mg／m2， ATG 40mg／kg， 马利兰 8mg／kg加异基因外周血干细胞移植治疗复发性难治性淋巴瘤4例。4例供者均系患者亲属，其中1例供受者HLA有一个位点不合，其余3例供受者HLA完全相合。结果：4例患者对预处理方案耐受良好，移植后无1例发生移植物排斥。迄今4例患者已完全缓解8～15个月。结论：用非骨髓清除性方案作造血干细胞移植预处理，安全有效，毒性低，可应用于年老体弱或有实质内脏损伤者。
Objective： To explore the feasibility and efficacy of nonmyeloablative allogeneic peripheral stem cell transplantation in the treatment of hematopoietic malignancy． Methods： Four patients with relapsing lymphoma who were not the candidates for a conventional myeloablative therapy because of older age and／or organ dysfunction received nonmyeloablative allo－PBSCT． Nonmyeloablative conditioning regimen （NACR） included fludarabine （180mg／m2）， anti－T－lymphocyte globulin （40mg／kg） and low dose Busulfan （8mg／kg）． Three patients had a HLA－identical related donor and one had an one－antigen－mismatched related donor． Results： Four patients achieved complete remission that have lasted for 8～15 months． No graft－rejection occurred in all of 4 patients in whom the chemotherapy was well tolerated． Conclusion： This result supports that nonmyeloablative stem cell transplantation is safe and effective with low toxicity and is feasible in high－age patients and the patients with poor general condition．
出处
《中国肿瘤临床》
CAS
CSCD
北大核心
2001年第9期685-688,共4页
Chinese Journal of Clinical Oncology
